Time filter

Source Type

St. Georg, Germany

Background and objectives: The aim of this study was to investigate tuberculosis (TB) in au-pairs in Germany and Austria and to assess the risk of infection for the host families. Methods: Reports from local health authorities were obtained between 2002 and 2010 (Bavaria, 12 cases) and from 2006 to 2010 (Baden-Wuerttemberg 6, North Rhine-Westphalia and Hesse, 1 each, additionally 2 from Austria). Results: 22 cases of tuberculosis were reported to the local health authorities, all of them concerning young female au-pairs, age 1927 years. Countries of origin were: Kenya (9), Georgia (4), Mongolia (3), Indonesia (2), Nepal, Russia, Romania, and Peru (1 each). In 17 au-pairs, sputum-smear positive pulmonary tuberculosis was diagnosed. Three au-pairs presented with extrapulmonary tuberculosis without or only with minor pulmonary involvement. In two asymptomatic cases, sputum-smear negative tuberculosis was diagnosed by screening. The time between entry and the beginning of symptoms was 7.5±5.8 months (019.3). 10.0±6.1 weeks (range 320 weeks) elapsed between the first symptoms and the diagnosis. No infection of the host families was caused by 5 au-pairs who had no or only minor pulmonary involvement. In 17 au-pairs with high mycobacterial burden, the infection rate increased with the duration of time between symptoms and diagnosis (111 infections per au-pair). A total of 46 contacts (21 children, 25 adults) were infected. 17 children received chemoprophylaxis with isoniazid (INH); none of them developed active disease. One child out of four who did not get INH was diagnosed with pulmonary TB. In addition, 5 out of 24 adults without chemoprevention developed active TB. 4 TB-strains were drug-resistant strains, one of them multidrug-resistant. Conclusions: In au-pairs from countries with high burden of tuberculosis, long lasting cough and weariness should prompt diagnostics for tuberculosis. By screening, the disease can be detected before it gets infectious. If infection has occurred, chemoprevention with INH for nine months can prevent overt tuberculosis. © Georg Thieme Verlag KG Stuttgart - New York. Source

Hakenberg O.W.,Universitatsklinikum Rostock
Urologe | Year: 2016

Pelvic lipomatosis is a rare benign disease characterized by increased pelvic fatty tissue of unknown origin, which leads to encroachment on the pelvic organs. This can lead to symptoms due to narrowing of the bladder and in some cases also of the rectum as well as distal obstruction of the ureter. Symptomatic disease seems to occur more commonly in men with unspecific lower urinary tract symptoms, constipation and hydronephrosis. Obstruction of the upper urinary tract necessitates operative treatment. As the etiology is unclear an appropriate causal treatment is not available. © 2016, Springer-Verlag Berlin Heidelberg. Source

Asthma is not a new disease. It is one of the most common chronic disorders affecting approximately 45% of adults and more than 10% of children in Germany. This turns asthma into one of the most prevalent chronic disorders. Over the last century ideas about its pathogenesis have changed many times. While around one hundred years ago asthma was often considered a neurotic disease, changes in airway smooth muscle, mast cell accumulation and activation or specific mediators such as platelet-activating factor have since been incriminated in its pathogenesis. Eosinophils, cytokines and T-lymphocytes were favourites some time later. Nowadays, and this is unlikely to be the end of the story asthma is considered as a complex disorder of the adaptive immune system. Therapeutic approaches have changed dramatically, too. While until about 30 years ago asthma was still considered a Smooth muscle disorder, recurrent attacks of asthma which required frequent, mostly nocturnal interventions, status asthmaticus, or the necessity of mechanical, invasive ventilation have markedly decreased. In view of the asthma epidemic in recent years, this development suggests that current treatments are at least partially effective. In spite of this patients with asthma are often only moderately well controlled with considerable morbidity from the disease as well as its treatment. Thus, despite recent advances in diagnosis and treatment, asthma is still not a trivial disease and future attempts at improving the care of those affected are warranted. The developments of the past 100 years as well as a careful look into the future are presented in this review. © 2010 Georg Thieme Verlag KG Stuttgart · New York. Source

Lommatzsch M.,Universitatsklinikum Rostock
Deutsche Medizinische Wochenschrift | Year: 2016

Current guidelines of the global initiative for asthma (GINA) recommend the addition of biologics in step 5 of the stepwise asthma treatment approach. This review gives an overview on the effects and the clinical role of antibodies targeting immunoglobulin E, IgE (Omalizumab), Interleukin-5, IL-5 (Mepolizumab, Reslizumab) or the IL-5 receptor (Benralizumab). In addition, potential future treatment options of refractory asthma with antibodies (for instance Dupilumab) are discussed. Source

Hehrlein C.,Albert Ludwigs University of Freiburg | Richardt G.,Segeberger Kliniken | Wiemer M.,Herz Diabetes Zentrum NRW | Schneider H.,Universitatsklinikum Rostock | Dietz U.,Deutsche Klinik fur Diagnostik
EuroIntervention | Year: 2011

Aims: Drug-eluting balloons (DEB) have recently emerged as a valuable treatment option for patients with coronary in-stent restenosis (ISR). However, little information exists on results of DEB therapy of in-stent restenosis from drug-eluting stents (DES). Methods and results: The Pantera Lux balloon catheter, a novel DEB releasing paclitaxel with a BTHC matrix was studied in a prospective, multicentre first-in-man trial of patients with ISR either from bare metal stents (BMS) or drug-eluting stents (DES). Here we report on the clinical and angiographic follow-up of the first 45 Pantera Lux patients after six months. The mean age (±SD) of the studied ISR patients was 69±9 years (82% males, 18% females). The distribution of BMS and DES in these patients was 53% and 47%, respectively. Success of deployment of the device was 100%. After six months, the major adverse cardiac event (MACE) rate was 7.7% including one post-procedural non-fatal myocardial infarction, one target lesion- and one target vessel- revascularisation (each clinically driven). Angiographic in-stent late lumen loss was 0.03±0.35 mm (BMS: -0.08±0.37 mm, DES: 0.15±0.28 mm) as assessed by an independent angiographic core laboratory. Conclusion: Treatment of coronary in-stent restenosis with the Pantera Lux paclitaxel-releasing balloon catheter shows very promising preliminary 6-month results, irrespective of whether the initially implanted stent was a bare metal- or a drug-eluting stent. © Europa Edition 2011. All rights reserved. Source

Discover hidden collaborations